John B. Mumm

ARMO BioSciences, Inc. develops immunotherapy for the treatment of cancer, cardiovascular diseases, fibrosis, and inflammation. Its lead product candidate is AM0010 (pegilodecaki). The company was founded by Peter Van Vlasselaer, Martin Oft, and John B. Mumm on June 23, 2010 and is headquartered in Redwood, CA.

Introgen Therapeutics, Inc. is a biopharmaceutical company focuses on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. The company develops molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. The company maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility. It was founded in June 1993 and is headquartered in Austin, TX.

Bacterial Barcodes, Inc. provides equipment, reagents, and software for microbial genotyping of bacteria and fungi. The company was founded on November 10, 2005 and is headquartered in Durham, NC.

Deka Biosciences, Inc. is a biotech company based in Germantown, MD. Deka Biosciences is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases. The company has developed disease-specific diakines™ that are designed to maximize patient benefits through improved pharmacokinetics/pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Deka Biosciences aims to build specific targeted therapies for everyone by developing a better understanding of each patient's immune response to different diakines™. The company was founded in 2019 by John B. Mumm and Pavel Khrimian, with John B. Mumm serving as the CEO since then.